Navigation Links
PDK1 in Medical News

Arno Therapeutics Appoints William F. Hamilton to Board of Directors

...ted second-generation products in its class. Arno is also developing two pre-clinical compounds. AR-12 is a potential first-in-class, orally available pdk1 inhibitor that blocks the PI3K/Akt pathway undergoing IND-enabling studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC and Akt pa...
PDK1 in Medical Technology

FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway

PARSIPPANY, N.J., May 11 /PRNewswire-FirstCall/ -- Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced that the U.S. Food and Drug Administration ("FDA") accepted the Company's Investigational New Drug ("IND") application for the us...
PDK1 in Biological Technology

Arno Therapeutics to Deregister its Common Stock under the Exchange Act

...firms the improved pharmacokinetic properties. Arno is also developing two pre-clinical compounds. AR-12, a potential first-in-class, orally available pdk1 inhibitor that blocks the PI3K/Akt pathway, has completed IND-enabling studies. AR-42, an orally available, targeted inhibitor of the Pan-DAC and Akt ...

Arno Therapeutics Reports 2008 Year-End Financial Results

...ted second-generation products in its class. Arno is also developing two pre-clinical compounds. AR-12 is a potential first-in-class, orally available pdk1 inhibitor that blocks the PI3K/Akt pathway undergoing IND-enabling studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC and Akt pa...

FDA Accepts IND for Arno Therapeutics' Pan-DAC / Akt Inhibitor, AR-42

...ted second-generation products in its class. Arno is also developing two pre-clinical compounds. AR-12 is a potential first-in-class, orally available pdk1 inhibitor that blocks the PI3K/Akt pathway undergoing IND-enabling studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC and Akt pa...

Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference

...ted second-generation products in its class. Arno is also developing two pre-clinical compounds. AR-12 is a potential first-in-class, orally available pdk1 inhibitor that blocks the PI3K/Akt pathway that is undergoing IND-enabling studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC an...

Arno Therapeutics Announces Second Quarter 2008 Financial Results

...ed second-generation products in its class. Arno is also developing two pre-clinical compounds. AR- 12 is a potential first-in-class, orally available pdk1 inhibitor that blocks the PI3K/Akt pathway undergoing IND-enabling studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC and Akt pa...

Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer

...ted second-generation products in its class. Arno is also developing two pre-clinical compounds. AR-12 is a potential first-in-class, orally available pdk1 inhibitor that blocks the PI3K/Akt pathway undergoing IND-enabling studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC and Akt pa...
PDK1 in Biological Products

Mouse Anti-PDK1 Docking Motif, phospho (Ser / Thr) Monoclonal Antibody, Unconjugated, Clone 18A2 from Cell Signaling Technology

Description:... Phospho- (Ser/Thr) pdk1 Docking Motif (18A2) Mouse mAb...
Company:Cell Signaling Technology
Other Tags
(Date:8/20/2014)... By Barbara Bronson Gray ... News) -- Although it,s extremely rare, colds, flu and ... of elevated risk for stroke in children, a new study ... have a stroke in the United States, said Dr. Heather ... neurology and pediatrics at the University of California, San Francisco ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, ... long been an option, but a new study shows that ... most common reasons women didn,t undergo reconstruction was that they ... or they were focused on their cancer treatment," said lead ... Sloan Kettering Cancer Center, in New York City. Also ...
(Date:8/20/2014)... to treating kidney failure by removing waste products from ... who suddenly developed the condition, in an analysis led ... Medicine. , Their findings, published online in the journal ... method that is standardly used for people with sudden ... the patient. , "Our findings question the accepted notion ...
(Date:8/20/2014)... treating cancer - using Botox. A study presented in ... shows that cancer growth could be suppressed by ... to cancer stem cells. The approach thus treated the ... safe and efficient. The researchers have thus far tested ... on humans. , The nervous system is crucial in ...
(Date:8/20/2014)... A common approach to treating kidney failure by ... survival chances for people who suddenly developed the condition, ... University of Pittsburgh School of Medicine. , ... PLOS One , suggest acute hemodialysis, an aggressive method ... failure, may not provide a definitive benefit to the ...
Breaking Medicine News(10 mins):Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Treating gastric cancer -- with Botox 2Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2
(Date:8/20/2014)... suffered concussions ready to return to action? A new ... athletes who head back on the field with medical ... their abilities to simultaneously walk and do simple mental ... their balance and/or altered walking speed, was found in ... returned to activity in less than a month. Seven ...
(Date:8/20/2014)... few years, Virginia Tech,s Wu Feng has built upon ... the "Computing in the Cloud" program, and synergistically complemented ... award from the Air Force on "big computing" for ... the National Institutes of Health on "big data" for ... "parallel computing" aspects from each grant, he was able ...
(Date:8/20/2014)... A new gene therapy developed by researchers at ... shown to protect mice from a life-threatening heart condition ... new therapeutic avenue," said Yi Lai, Ph.D., the leading ... the MU School of Medicine,s Department of Molecular Microbiology ... we hope this could lead to a treatment for ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Gene therapy protects mice from lethal heart condition, MU researchers find 2
Other Contents